The androgen receptor (AR) plays a critical role in the development of castration-resistant prostate cancer (CRPC) as well as in the resistance to the second-generation AR antagonist enzalutamide and the selective inhibitor of cytochrome P450 17A1 (CYP17A1) abiraterone. Novel agents targeting AR may inhibit the growth of prostate cancer cells resistant to enzalutamide and/or abiraterone. Through a high-throughput/high-content screening of a 220,000-member small molecule library, we have previously identified 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone (IMTPPE) (SID 3712502) as a novel small molecule capable of inhibiting AR transcriptional activity and protein level in C4-2 prostate cancer cells. In this study, we show that IMTPPE inhibits ARtarget gene expression using real-time polymerase chain reaction, Western blot, and luciferase assays. IMTPPE inhibited proliferation of AR-positive, but not AR-negative, prostate cancer cells in culture. IMTPPE inhibited the transcriptional activity of a mutant AR lacking the ligand-binding domain (LBD), indicating that IMTPPE inhibition of AR is independent of the LBD. Furthermore, animal studies showed that IMTPPE inhibited the growth of 22Rv1 xenograft tumor, a model for enzalutamide-resistant prostate cancer. These findings suggest that IMTPPE is a potential lead compound for developing clinical candidates for the treatment of CRPC, including those resistant to enzalutamide. (Endocrinology 158: 3152-3161, 2017) A ndrogen deprivation therapy (ADT) is the standard treatment of patients with metastatic prostate cancer (1). However, ADT is not curative, and treated patients eventually develop castration-resistant prostate cancer (CRPC) (2, 3). CRPC is currently incurable, and it is predicted that in 2017 prostate cancer will be the third 3152 https://academic.oup.com/endo Endocrinology,
most common cause of cancer death among men in the United States (4) . ADT acts through inhibition of the androgen receptor (AR), a member of the steroid nuclear receptor superfamily (5) (6) (7) . AR is an androgen-dependent transcription factor that regulates the expression of androgenresponsive target genes (8) (9) (10) (11) . Multiple studies have shown that the AR is activated via multiple mechanisms in CRPC, including AR overexpression, mutation, hypersensitization, and/or intratumoral androgen synthesis (12) (13) (14) (15) (16) (17) (18) . Overexpression and knockdown studies have demonstrated that AR is a key molecular determinant (19, 20) and remains the most important therapeutic target for prostate cancer and CRPC.
Several agents targeting androgen synthesis or antagonizing AR ligand binding have been developed for prostate cancer treatment that act either directly or indirectly through the AR ligand-binding domain (LBD). Abiraterone, a potent inhibitor of testosterone synthesis, and enzalutamide, a novel AR antagonist, inhibit AR signaling and prolong the survival of patients with CRPC for 4 to 6 months on average (21) (22) (23) (24) . Rising serum PSA levels in patients treated with abiraterone or enzalutamide are indicative of the development of resistance and suggest that AR is reactivated and drives the resistance [reviewed by Mostaghel (25) ]. Small molecules targeting the N-terminal domain (NTD) or DNA-binding domain of AR are being developed with the expectation that they may overcome the resistance of prostate cancer cells to LBD-targeted agents (26, 27) . The identification and characterization of novel compounds capable of inhibiting AR may lead to new treatment options for patients with CRPC, particularly those who relapse after treatment with abiraterone and/or enzalutamide.
We identified 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone (IMTPPE) (SID 3712502), a novel small molecule that inhibits AR transcriptional activity and protein levels in C4-2 prostate cancer cells, in a highthroughput/high-content screening campaign of ;220,000 small molecules (28) . In this paper, we characterize IMTPPE as a novel AR antagonist in several different prostate cancer cell lines and evaluate its potential in the treatment of CRPC tumors in animal models.
Materials and Methods

Cell culture
LNCaP (29) , CWR22Rv1 (22Rv1) (30) , DU145 (31) , and PC3 (32) prostate cancer cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA). C4-2 (33), LAPC4 (34) , and CWR-R1 (16) were kindly provided by Dr. Leland W.K. Chung (Cedars-Sinai Medical Center), Robert Reiter (University of California, Los Angeles), and Christopher W. Gregory (University of North Carolina), respectively. Cell lines LNCaP, 22Rv1, and C4-2 were authenticated in 2016 using DNA fingerprinting by examining microsatellite loci in a multiplex PCR reaction (AmpFlSTR Identifiler PCR Amplification Kit; Applied Biosystems, Foster City, CA) by the University of Pittsburgh Cell Culture and Cytogenetics Facility. PC3 cell lines were obtained from ATCC in 2016. ATCC performed authentication for PC3 cell lines using short tandem repeat profiling. No authentication was performed for DU145, CWR-R1, or LAPC4. All cell lines, except DU145, were grown in Roswell Park Memorial Institute (RPMI) 1640 media with supplementation of 10% fetal bovine serum (FBS) and 100 mg/mL penicillin/streptomycin in a 37°C incubator with 5% CO 2 . DU145 cells were cultured in Dulbecco's modified Eagle medium supplemented with 10% FBS and 100 mg/mL penicillin/streptomycin. For hormone treatment, cells were grown to 60% to 80% confluency and then serum starved overnight in either serum-free media or media supplemented with 5% charcoal-dextran-stripped FBS RPMI. The synthetic androgen methyltrienolone (R1881; Perkin Elmer, Boston, MA) was then added to the charcoaldextran-stripped FBS RPMI media, and cells were treated with the indicated amounts of R1881 for 24 hours. For inhibition of AR, IMTPPE or enzalutamide was added 2 hours prior to treatment with R1881.
Cell proliferation assay
Cells were plated in 4-chamber slides or 12-well plates at 50% to 60% confluency in RPMI 1640 complete medium, which contains castrate level of testosterone (35) . After 24 hours, the cells were treated with IMTPPE at the indicated concentrations for 48 hours, and 5-bromo-2 0 -deoxyuridine (BrdU) incorporation was assayed according to the manufacturer's instructions (BrdU staining kit; catalog no.93-3943; Invitrogen). The percentage of BrdU-positive cells was determined and then normalized to control cells treated with dimethyl sulfoxide (DMSO) vehicle to generate a relative BrdU index.
Luciferase assay
The PSA6.1 luciferase reporter construct (26, 36) was generously provided by Dr. Marianne Sadar (British Columbia Cancer Agency). DNA was purified with the plasmid Maxi prep kit (Qiagen, Valencia, CA). LNCaP, C4-2, and 22Rv1 cells were plated at 60% to 80% confluency in 12-well plates. For hormone induction, R1881 was added to media with 5% to 10% charcoal-dextran-stripped FBS as described previously. After 24 to 48 hours, cells were lysed, and luciferase activity was measured using a luciferase assay kit (Promega, Sunnyvale, CA) and a Turner luminometer (Promega) following the manufacturer's recommendations. Firefly luciferase activity was normalized to Renilla luciferase activity. The mouse mammary tumor virus (MMTV)-luciferase reporter was kindly provided by Dr. Donald DeFranco (Univ. of Pittsburgh). The transfected MMTV-luciferase reporter was induced by 0.5 mM dexamethasone (37) . All experiments were performed in triplicate and repeated at least twice. Standard error of the mean (SEM) was determined using GraphPad InStat software (San Diego, CA). Significance was determined by Student t test.
Western blot
Cultured cells in RPMI 1640 complete medium were treated with IMTPPE or vehicle DMSO at the indicated concentrations (in micrometers) for 48 hours. The cells were then harvested in radioimmunoprecipitation assay buffer for Western blot analysis using antibodies for AR (catalog no. sc-816; Santa Cruz Biotechnology, Dallas, TX), PSA (C-19, sc-7638; Santa Cruz Biotechnology), GFP (catalog no. SC-8334; Santa Cruz Biotechnology), and GAPDH (catalog no., sc-25778; Santa Cruz Biotechnology). GAPDH was included as a loading control.
Real-time PCR
C4-2 cells were cultured in 6-well plates with complete RPMI-1640 medium for 2 days. Cells were then treated with DMSO, 1 nM R1881, and/or 10 mM IMTPPE for 24 hours. C4-2 total RNA was extracted from each experimental group using the RNeasy Mini kit (catalog no. 74106; Qiagen, Hilden, Germany) according to manufacturer's protocol. Total RNA (500 ng) was used in each reverse transcription reaction using a PrimeScript RT reagent kit (catalog no. RR037A; TaKaRa -Clontech, Mountain View, CA). Real-time PCR was performed on an ABI Step-One Plus system (Applied Biosystems, Foster City, CA) using SYBR Advantage qPCR Premix (catalog no. 639676; TaKaRa). Expression of the indicated genes was normalized to the GAPDH mRNA level. The sequences of the primers are 
Xenografts
The BALB/c strain of athymic SCID mice was obtained from Charles River Laboratory (Wilmington, MA), and animals were kept in accordance with the National Institutes of Health guidelines under standard animal housing conditions for the Care and Use of Experimental Animals. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh and were conducted in strict accordance with the standards for humane animal care and use as set by the Animal Welfare Act and the National Institutes of Health guidelines for the use of laboratory animals.
To establish xenograft tumors, approximately 1 3 10 6 22Rv1 or PC3 cells suspended in 250 mL media were gently mixed with 250 mL of Matrigel (Becton Dickinson Labware, Bedford, MA) and then inoculated subcutaneously in the flank region of 6-to ;8-week-old male athymic SCID mice using a 25-gauge needle. 22Rv1 or PC3 xenograft tumors were measured on alternate days, and volume was calculated by the modified ellipsoid formula (length 3 width 2 3 0.52) (38 
Statistical analysis
Prism 5.0 (GraphPad Software, Inc.) and MS Excel 2013 (Microsoft) were used for statistical analysis and graphical composition. Data were expressed as the mean 6 SEM, and statistical significance was determined by one-way analysis of variance, two-way analysis of variance, or Student t test, as appropriate. Tumor volume data were expressed as the mean 6 SEM, and statistical significance was determined by MantelCox log-rank or by Student t test as appropriate. A P value of ,0.05 was considered statistically significant.
Results
IMTPPE inhibits endogenous AR, AR splice variants, and AR-target gene expression levels
We recently reported the identification of IMTPPE as a small molecule capable of inhibiting the expression of AR-target gene PSA at low dosage (2 mM) and down-regulating AR at high dosage (10 mM) in C4-2 prostate cancer cells (28) . This study tested the effects of IMTPPE exposure on the expression of PSA and AR proteins in additional AR-positive prostate cancer cell lines (i.e., LNCaP, LAPC4, 22Rv1, and CWR-R1). Western blot analysis revealed that 2 mM or higher levels of IMTPPE inhibited PSA protein expression levels in LNCaP, LAPC4, 22Rv1, and C4-2 cells (Fig. 1A) . No PSA protein expression was detected in CWR-R1 cells in our experiments (Fig. 1A) . At 10 mM or higher, IMTPPE exposure also inhibited AR and AR splice variant (ARv) expression levels. Real-time PCR analysis showed IMTPPE inhibition of the R1881-induced mRNA expression of PSA, EAF2, ELL2, TMPRSS-2 (40), and NKX3.1 (41, 42) in C4-2 cells to levels that were similar or below the uninduced baseline (Fig. 1B) . These findings demonstrated that IMTPPE exposure inhibited AR-target gene expression at both the mRNA and protein levels in prostate cancer cells.
IMTPPE inhibits the AR-dependent promoter but not the glucocorticoid receptor-dependent promoter
To test if IMTPPE can inhibit AR transactivation, we performed a luciferase assay using the PSA6.1-Luc construct, which contains a 6.1-kb PSA enhancer and promoter, to drive the expression of luciferase (26, 36) . IMTPPE inhibited the PSA-luciferase activity in a dosedependent fashion with an IC 50 of about 1 mM in CRPC C4-2 cells cultured in complete RPMI medium ( Fig. 2A) . In a C4-2 subline, C4-2-PSA-rl, which were generated by stable cotransfection of with a PSA-luciferase reporter vector (pPSA6.1) and a Renilla luciferase reporter vector (43), IMTPPE inhibited its high basal PSA-luciferase activity and the agonist-induced PSA-luciferase activity in the presence of 0.1 or 1 nM R1881, a synthetic androgen (Fig. 2B ). In the presence of 10 nM R1881, IMTPPE weakly inhibited PSA-luciferase activity (Fig. 2B) . Consistent with its inhibition of the PSA-luciferase activity, IMTPPE also inhibited hormone-induced endogenous PSA protein expression in C4-2 cells (Fig. 2C ). These observations suggest that IMTPPE can inhibit the AR-mediated transactivation of its target genes. To evaluate the selectivity and specificity of IMTPPE inhibition of AR, we examined whether IMTPPE could inhibit glucocorticoid receptor (GR)-mediated transactivation, another member of the steroid nuclear receptor superfamily. The transfected MMTV promoter was not active in C4-2 cells without GR cotransfection, and it can be activated by dexamethasone when the cells were cotransfected with GR expression vector (44) . IMTPPE did not inhibit dexamethasone-induced, GRdirected, MMTV promoter-driven luciferase activity (Fig. 2D) . These data demonstrated that IMTPPE selectively inhibited AR vs GR transactivation and is likely to be specific for AR.
IMTPPE inhibits AR constructs lacking the LBD
Because the structure of IMTPPE (28) is very different from other well-established antiandrogens (45, 46) , the mechanism of IMTPPE inhibition of AR signaling is likely to be different from molecules that target the LBD of AR. Thus, IMTPPE may be able to inhibit AR signaling in prostate cancer cells that are resistant to LBD-targeting antiandrogens like enzalutamide. 22Rv1 is a wellestablished enzalutamide-resistant prostate cancer cell line that expresses both AR and AR splice variants, including ARv7 (47) . IMTPPE inhibited PSA-luciferase activity in the presence and absence of the synthetic androgen R1881 in 22Rv1 cells (Fig. 3A) . This observation suggested that IMTPPE may inhibit both full-length AR and Luc in C4-2 cells. C4-2 cells in androgen-free media were transiently transfected with GFP-NAR or GFP together with PSA6.1 Luc and pRL-CMV overnight prior to treatment with 10 mM IMTPPE for 24 hours. Western blot analysis was performed using anti-GFP and anti-GAPDH antibodies on transfected C4-2 cell samples prepared in parallel. Significance was determined by Student t test. *P , 0.05; **P , 0.01; ***P , 0.001.
AR splice variants that lack a LBD. To test whether IMTPPE could indeed inhibit AR lacking a LBD, we transfected GFP with AR lacking the LBD (NAR) (48) or GFP control vector into C4-2 cells. In the absence of androgens, GFP-transfected cells exhibited very low PSA-luciferase activity, whereas GFP-NAR-transfected cells had a robust PSA-luciferase response, which was inhibited by IMTPPE (Fig. 3B) . In Western blot analysis, IMTPPE caused no obvious change in transfected GFP-NAR protein levels in C4-2 cells.
IMTPPE inhibits AR-positive, but not AR-negative, prostate cancer cells in culture
To evaluate the efficacy, potency, and specificity of IMTPPE's inhibition of AR-dependent proliferation in prostate cancer cells, we tested its effect on the proliferation of AR-positive LNCaP, C4-2, 22Rv1, and ARnegative DU145 and PC3 prostate cancer cells. IMTPPE inhibited the proliferation of AR-positive cells (LNCaP, C4-2, and 22Rv1 cells) but not AR-negative cells (DU145 and PC3 cells), suggesting that IMTPPE inhibition of cell proliferation is mediated through AR (Fig. 4A) . In comparison, enzalutamide, a next-generation AR antagonist, inhibited LNCaP and C4-2 cells but not 22Rv1, DU145, and PC3 cells (Fig. 4B) . 22Rv1 is known to be resistant to enzalutamide, possibly due to the expression of androgen-independent ARv7 (47, 49). These observations suggested that IMTPPE might be effective at inhibiting ARv7-positive and enzalutamide-resistant prostate cancer cells. However, our experiments did not directly test if IMTPPE inhibits ARv7, and further studies are needed to specifically address this issue.
IMTPPE inhibits 22Rv1 xenograft tumor growth in mice
To further evaluate the potential of IMTPPE in the treatment of prostate cancer, particularly AR-positive enzalutamide-resistant prostate cancer, we tested the effect of IMTPPE on 22Rv1 xenograft tumor growth in SCID mice. The animals were castrated when 22Rv1 tumors reached 200 mm 3 , randomized, and treated with IMTPPE at 25 mg/kg body weight or vehicle control every other day starting 4 days after castration. IMTPPE treatment inhibited the 22Rv1 tumor growth more than 50% as compared with the vehicle treatment (Fig. 5A) . IMTPPE had no detectable effect on animal body weight (Fig. 5B) . The median survival time of mice treated with IMTPPE was 50 days, which was significantly longer than the 23-day median survival time of the control group (Fig. 5C ). As expected, IMTPPE did not inhibit the growth of AR-negative PC3 tumors in mice (Fig. 5D) . These results showed that IMTPPE can specifically inhibit AR-positive prostate cancer in vivo and could serve as a lead compound to be optimized and developed into a drug to treat patients with castrationresistant prostate cancer, including those resistant to enzalutamide.
Discussion
The studies herein indicate that IMTPPE is a novel ARtargeting small molecule capable of inhibiting CRPC. IMTPPE reduced AR and/or ARv expression levels, inhibited the expression of AR-target genes, and blocked the proliferation of AR-positive prostate cancer cells. Unlike commonly used AR antagonists like enzalutamide, which target the LBD, IMTPPE inhibition of AR appears to be independent of the LBD. Animal studies demonstrated that IMTPPE inhibited the growth of 22Rv1 xenograft tumors, indicating that it has potential as a lead compound that could be optimized and developed into a clinical candidate for the treatment of CRPC, including those resistant to enzalutamide and likely other antiandrogens. IMTPPE inhibition of prostate cancer appears to be mediated through targeting AR signaling because it only inhibited the proliferation of AR-positive but not ARnegative prostate cancer cell lines. Also, IMTPPE appears to be selective and/or specific for AR signaling because it did not inhibit GR, another member of the steroid nuclear receptor superfamily. IMTPPE inhibits the AR in two diverse ways. At lower concentrations, IMTPPE inhibited the transcriptional activity of AR without affecting AR protein expression levels, which were only reduced at higher compound concentrations. However, the mechanisms by which IMTPPE differentially inhibits AR transcription activation and protein levels have not been resolved and are the subject of further investigation.
The potential for IMTPPE to overcome prostate cancer resistance to enzalutamide, and perhaps other antiandrogens, is clinically important. A major mechanism leading to enzalutamide resistance in prostate cancer is thought to be the expression of AR splice variants, including ARv7, which lack the LBD and are independent of androgens. LBD-targeting AR antagonists, including enzalutamide, are not effective against prostate cancer cells expressing AR splice variants, such as 22Rv1 (49, 50) . Because IMTPPE was able to inhibit the transcription activation by both full-length AR and an AR mutant lacking the LBD (Figs. 2 and 3) , it should also be effective on CRPC cells expressing AR splice variants, which is supported by our data showing IMTPPE inhibition of 22Rv1 prostate cancer both in culture and in tumor xenografts (Figs. 4 and 5) . Because the mechanism of IMTPPE inhibition of AR is very different from IMTPPE may represent a new class of AR antagonists. Its structure is very different from LBD-targeting AR antagonists, including hydroxyflutamide, bicalutamide, and enzalutamide (45, 46, 51) . Also, its mechanism of action appears to be mediated through the NTD and/or DNA binding domain and hinge region of AR because IMTPPE was able to inhibit NAR transactivation of the PSA promoter/enhancer in the luciferase assay. Thus, the mechanism of IMTPPE inhibition of AR is distinctly different from these LBD-targeting AR antagonists. IMTPPE is also structurally very different from EPI-001, a novel AR antagonist that binds to the NTD of the AR (26) . Further studies are needed to test whether IMTPPE can bind to the NTD of the AR.
In summary, we report the characterization of IMTPPE, a potential AR antagonist capable of inhibiting both full-length AR and AR splice variant. IMTPPE appears to target AR signaling specifically and can inhibit AR-positive, but not AR-negative, prostate cancer cells in culture and in animals. Future studies will explore the potential of IMTPPE as a lead compound for the development of new treatment options for CRPC, including those resistant to enzalutamide, abiraterone, and other antiandrogens.
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